Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Shanawaz v. Intellipharmaceutics International Inc. et al
Case Number:
1:17-cv-05761
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
-
November 12, 2019
Opioid Co. Inks $1.6M Deal To End Suit Over FDA Rejection
Canadian drugmaker Intellipharmaceutics International Inc. has agreed to pay investors $1.6 million to settle a proposed class action alleging the company overstated opioid painkiller Rexista's ability to deter abuse before the U.S. Food and Drug Administration rejected its approval.
-
July 31, 2017
Investors Sue Abuse-Deterrent Opioid Co. After FDA Setback
Intellipharmaceutics International Inc. allegedly lied to its investors about how sure it was its abuse-deterrent opioid painkiller Rexista actually prevented abuse when applying for U.S. Food and Drug Administration approval, a potential class told a New York federal court Friday.